| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/31/2002 | US20020013325 Useful as glycoprotein IIb/IIIa antagonists for prophylaxis thrombosis, therapy of atheroschlerosis, arterioschlerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischemic attacks and strokes |
| 01/31/2002 | US20020013322 Novel compounds for enhancing chemotherapy |
| 01/31/2002 | US20020013321 Used as ligands for opioid receptors, for therapy of neurological and gastrointestinal disorders |
| 01/31/2002 | US20020013320 Use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
| 01/31/2002 | US20020013319 For therapy of tumor or restenosis |
| 01/31/2002 | US20020013316 Nitrogen-containing heterocyclic carboxamide derivatives or salts thereof and antiviral agents comprising the same |
| 01/31/2002 | US20020013315 For therapy Alzheimer's disease |
| 01/31/2002 | US20020013313 4,5-dihydro-1,3-dithia-4-aza-acenaphthylene-3,3-dioxide compounds for example; treating ischemia, Alzheimer's disease, schizophrenia; alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) |
| 01/31/2002 | US20020013312 Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them |
| 01/31/2002 | US20020013311 Of the eye, nose, skin, ear, gastrointestinal tract, airways or lung and preventing or treating manifestations of systemic mastocytosis |
| 01/31/2002 | US20020013310 Inhibitors of the activity of Factor Xa such as 3-((1-(4-Aminoquinolin-7-ylmethyl)-2-oxopyrrolidin-3-(R)-yl)-( 5- chloro-1H-indol-2-ylmethyl)amino)propionic acid methyl ester |
| 01/31/2002 | US20020013309 Pharmaceutical compositions and methods for use |
| 01/31/2002 | US20020013308 Comprising insulin resistance improving agents in combination with drugs selected from angiotensin II receptor antagonists and angiotensin converting enzyme inhibitors with a diluent or carrier |
| 01/31/2002 | US20020013307 Administering compounds such as omapatrilat or gemopatrilat |
| 01/31/2002 | US20020013306 Terpyridine-platinum(ii) complexes |
| 01/31/2002 | US20020013305 Aqueous solvent for corticosteroids |
| 01/31/2002 | US20020013304 As needed rather than involving chronic pharmacotherapy; formulations and kits |
| 01/31/2002 | US20020013303 Administering in dosage to suppress aldosterone-mediated myocardial fibrosis without increasing sodium excretion and without reducing potassium retention by the body; administering spironolactone; tablets, capsules |
| 01/31/2002 | US20020013301 In an oral dosage form, providing a combination product analgesically effective when administered orally, but which is aversive in addicts at the same dose or higher dose than prescribed; prevention of drug abuse, drug dependency |
| 01/31/2002 | US20020013300 Methods for improving size and appearance of a wound |
| 01/31/2002 | US20020013299 For enhancing the chemotherapeutic treatment of tumor cells in a mammal with an antineoplastic alkylating agent, which causes cytotoxic lesions at the O6-position of guanine; O6-alkylguanine-DNA alkyltransferase (AGT) inactivator |
| 01/31/2002 | US20020013298 Such as multiple sclerosis, by administering antimicrotubule agent: epothilones, discodermolide, deuterium oxide, hexylene glycol, tubercidin, LY-290181, alumimum fluoride, glycine ethyl ester, or ethylene glycol bis(succinimidylsuccinate) |
| 01/31/2002 | US20020013297 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
| 01/31/2002 | US20020013296 Treating with agonists at kappa opioid receptors such as methyl-4-(2-glycyl-4-(trifluoromethylphenyl)acetyl)-3-(R,S)-((1 -pyrrolidinyl)-methyl)-1-piperazinecarboxylate |
| 01/31/2002 | US20020013295 Naaladase inhibitors for treating amyotrophic lateral sclerosis |
| 01/31/2002 | US20020013294 Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| 01/31/2002 | US20020013293 Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use |
| 01/31/2002 | US20020013292 Made by dissolving an amphiphilic heparin derivative comprising heparin conjugated to bile acids, sterols, or alkanoic acids in a water phase, dispersing the water phase in an organic phase to form an emulsion, drying the emulsion |
| 01/31/2002 | US20020013291 Reperfusion injury; 2-Deoxy-6-O-(2-deoxy-4-O-phosphono-3-O-(3-tetradecanoyloxytetradecanoyl)-2 -(3-octadecanoyloxy-tetradecanoylamino)-beta-D-glucopyranosyl)-2-(3 -hexadecanoyloxytetradecanoylamino)-D-glucopyranose |
| 01/31/2002 | US20020013290 Intraperitoneal administration of adenosine for the treatment or prevention of gastrointestinal or systemic diseases |
| 01/31/2002 | US20020013289 P2Y2 and/or P2Y4 purinergic receptor agonists e.g., nucleotides of adenosine, cytidine and uridine, dinucleotides and analogs; treating vaginal dryness associated with menopause, chemotherapy, and diseases; vulvar pain |
| 01/31/2002 | US20020013288 Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
| 01/31/2002 | US20020013281 11,12-Dideoxy-3-de((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L -ribohexopyranosyl)oxy) 6-0-methyl 3-oxo-12,11-(oxycarbonyl) ((4-(4-(4-aminophenyl)-1H-imidazol-1-yl)-butyl)imino))-erythromycin; grampositive bacteria, esp. staphyloccus |
| 01/31/2002 | US20020013280 Pharmaceutical composition for preventing and treating sexual dysfunction and vasculargenic disease comprising icariin |
| 01/31/2002 | US20020013279 Hematopoietic stimulation |
| 01/31/2002 | US20020013275 Inhibiting stenosis following vascular trauma or disease by administering a conjugate of a vascular smooth muscle binding protein that associates with a cell surface of the vascular smooth muscle coupled to a drug inhibiting cellular activity |
| 01/31/2002 | US20020013270 Administering a microbiocide to inhibit or eliminate at least one symptom of the disorder; also using a probiotic mixture including a replenishing gastrointestinal microbe; anxiolytic agents; autism; psychosis; attention deficit |
| 01/31/2002 | US20020013268 Synergistic effect of a sulfonylurea and/or non-sulfonylurea Kchannel blocker, and a phosphodiesterase 3 type inhibitor |
| 01/31/2002 | US20020013267 Inhibition of neonatal hyperbilirubinemia in breast fed infants |
| 01/31/2002 | US20020013266 Polymer stabilized neuropeptides |
| 01/31/2002 | US20020013261 Contacting a localized area of tissue with the polymer; treating ischemia |
| 01/31/2002 | US20020013260 Ginsenoside chemotherapy |
| 01/31/2002 | US20020013259 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders |
| 01/31/2002 | US20020013258 Novel stem cell factor formulations and methods |
| 01/31/2002 | US20020013257 Use of ligands to GABAB receptors |
| 01/31/2002 | US20020013256 Novel inhibitors of formation of advanced glycation endproducts (AGES) |
| 01/31/2002 | US20020012998 Gene transfer composition; for use in the transfection of mammalian cells |
| 01/31/2002 | US20020012992 Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor |
| 01/31/2002 | US20020012957 Plasma-like solution |
| 01/31/2002 | US20020012954 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth |
| 01/31/2002 | US20020012931 High specificity marker detection |
| 01/31/2002 | US20020012723 Containing sugar to provide freezing and thawing stability; foods, drinks; treatment of anemia |
| 01/31/2002 | US20020012715 Protecting cell from damage caused by free radicals by administering lipophilic antioxidant comprising vitamin E, beta carotene, extract of Lycopersicum esculentum, hydrophilic antioxidant comprising vitamin c, extract of vitis vinifera |
| 01/31/2002 | US20020012714 Combined marine and plant extract compositions |
| 01/31/2002 | US20020012713 Water-soluble complex of an extract of ginkgo biloba, process for the preparation thereof and composition comprising the same |
| 01/31/2002 | US20020012711 Compositions and methods for enhancing therapeutic effects |
| 01/31/2002 | US20020012709 Process and composition for controlling fecal hair excretion and trichobezoar formation |
| 01/31/2002 | US20020012706 Method of making granular pharmaceutical vehicle |
| 01/31/2002 | US20020012704 Water-insoluble drug particle process |
| 01/31/2002 | US20020012703 Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent |
| 01/31/2002 | US20020012702 Controlled release anti-inflammatory oral formulation and a process for the preparation thereof |
| 01/31/2002 | US20020012700 Portion of pseudoephedrine is contained in core whereby release into environment of use is sustained, cetirizine is contained as immediate-release component; antiallergens, spasmolytics |
| 01/31/2002 | US20020012696 In gene therapy and in in vitro and in vivo transfection |
| 01/31/2002 | US20020012695 Increased skin permeation of drug, and allows improved drug stability within the adhesive layer |
| 01/31/2002 | US20020012694 For delivery of 7 alpha -methyl-19-nortestosterone (MENT) |
| 01/31/2002 | US20020012691 Time-release agents, therapy in humans, veterinary medicine |
| 01/31/2002 | US20020012690 For therapy of arthropathy, osteoarthritis, gonarthrosis, periarthritis scapulo-humeralis, spondylitis deformans, etc. and foods or drinks having the effect of preventing or alleviating joint pains, cinealgia |
| 01/31/2002 | US20020012684 10-hydroxy-2-decenoic acid compounds for promoting desquamation/epidermal renewal of the skin and/or combating skin aging |
| 01/31/2002 | US20020012680 Compositions and methods for improved delivery of lipid regulating agents |
| 01/31/2002 | US20020012679 Process for manufacturing coated gabapentin or pregabalin particles |
| 01/31/2002 | US20020012678 Applying a mixture comprising polymerizable 1,1-disubstituted ethylene adhesive monomer and polydimethylsiloxane, a siloxane monomer or polymer, a fluorinated siloxane, and a siloxane on an area of tissue where scar tissue is present |
| 01/31/2002 | US20020012677 Pharmaceutical composition for treating dysmenorrhea and premature labor |
| 01/31/2002 | US20020012676 For inhibiting gastric acid secretion in mammals and man |
| 01/31/2002 | US20020012674 Bioadhesive complexes of polycarbophil and azole antifungal or antiprotozoal drugs |
| 01/31/2002 | US20020012665 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma |
| 01/31/2002 | US20020012642 Prophylaxis of erythema induced by exposure to ultraviolet or solar radiation by applying formulation containing lipoic acid in dermatologically acceptable carrier to exposed skin tissue |
| 01/31/2002 | US20020012641 Use of EGF-R protein tyrosine kinase inhibitors for preventing photoaging in human skin |
| 01/31/2002 | US20020012633 Sildenafil citrate chewing gum formulations and methods of using the same |
| 01/31/2002 | US20020012630 Producing wound in skin or another external body surface of an animal; permitting wound to heal in absence of test compound, or treating wound with a test compound; comparing wound healing, identifying a compound improves healing |
| 01/31/2002 | DE19881732C1 New phosphodiesterase inhibiting 2-phenyl-imidazotriazinone derivatives useful for treating e.g. cardiovascular, cerebrovascular and/or urogenital diseases |
| 01/31/2002 | DE10035513A1 Wirkstoffkombinationen bzw. Addukte aus Cyclodextrinen und mindestens einem Chinon und/oder mindestens einem Hydrochinon und Verwendung solcher Wirkstoffkombinationen in kosmetischen Zubereitungen Active compound combinations or adducts of cyclodextrins and at least one quinone and / or at least one hydroquinone and use of such drug combinations in cosmetic preparations |
| 01/31/2002 | DE10035144A1 Cyclische Aminosäurederivate Cyclic amino acid derivatives |
| 01/31/2002 | DE10034802A1 Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren Stable salts of O-acetylsalicylic acid with basic amino acids |
| 01/31/2002 | DE10033855A1 Transdermal therapeutic system for long-term treatment of hypertension, containing dicarboxylic acid angiotensin converting enzyme inhibitor converted into salt or ester derivative to improve stability |
| 01/31/2002 | DE10032537A1 Dermales System, enthaltend 2-(3-Benzophenyl)Propionsäure A dermal system, comprising 2- (3-benzophenyl) propionic acid |
| 01/31/2002 | DE10032456A1 Schnell zerfallende Darreichungsform zur Freisetzung von Wirkstoffen im Mundraum oder in Körperhöhlen Rapidly disintegrating dosage form for the delivery of drugs to the oral cavity or into body cavities |
| 01/31/2002 | CA2725819A1 Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| 01/31/2002 | CA2418333A1 Bicistronic influenza comprising two genes in tandem |
| 01/31/2002 | CA2418282A1 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/31/2002 | CA2418215A1 Novel fibroblast growth factor (fgf23) and methods for use |
| 01/31/2002 | CA2418204A1 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 01/31/2002 | CA2418194A1 Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors |
| 01/31/2002 | CA2417508A1 Glycosylated vegf-b and method for increasing the amount of soluble vegf-b |
| 01/31/2002 | CA2417192A1 Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| 01/31/2002 | CA2417189A1 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity |
| 01/31/2002 | CA2417127A1 Compounds and inhibitors of phospholipases |
| 01/31/2002 | CA2417108A1 A method for treating celiac disease |
| 01/31/2002 | CA2417097A1 Diagnosis of liver disease |
| 01/31/2002 | CA2417005A1 Regulators of ppar.delta.(.beta.) and their use in the treatment of obesity and insulin resistance |
| 01/31/2002 | CA2416821A1 Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder |